Form D · Biotechnology
BioExx Specialty Proteins Ltd.
Toronto, A6 · CIK 0001465222
Offering snapshot reported Jul 15, 2011 · SEC filing
- Reported sold
- $2.28M Offering amount: $2.28M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2011 | Initial | $2,284,354 | No comparison | 4 | SEC filing |
| Sep 8, 2010 | Initial | $1,524,806 | No comparison | 7 | SEC filing |
| Apr 16, 2010 | Initial | $1,313,218 | No comparison | 3 | SEC filing |
| Nov 9, 2009 | Initial | $3,771,308 | No comparison | 21 | SEC filing |
| Jun 10, 2009 | Initial | $827,608 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $78.3K
- Finders' fees
- $0
- Form D file number
- 021-162925
Each unit is comprised of one common share and one half of one common share warrant. Each whole warrant entitles the holder to acquire 1 common share at an approximate price of $1.5 per share until June 30, 2014.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Canaccord Genuity Inc. | 1020 | |
| Scotia Capital (USA) Inc. | 2739 | |
| Wellington West Capital Markets (USA) Inc. | 133617 |
Source: Form D, filed Jul 15, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher D. Carl | Director, Executive |
| Chris Carl | Director, Executive |
| Samah Garringer | Executive |
| Peter Lacey | Director |
| Henry Linsert | Director |
| John Macdonald | Director |
| Joseph Mac Donald | Director |
| John Mac Donald | Director |
| Paul Mc Clory | Director |
| William Ollerhead | Director |
| Will Ollerhead | Director |
| Christopher Schnarr | Director, Executive |
| Chris Schnarr | Director, Executive |
| Clinton Smith | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
219 Dufferin Street Suite 100 B
Toronto, A6, M6K 3J1
Toronto, A6, M6K 3J1